Qiagen NV (QGEN) reported better-than-expected financial results for the third quarter of fiscal 2025. The company posted earnings per share (EPS) of $0.61, surpassing Wall Street's consensus estimate of $0.60 by $0.01. Revenue matched expectations at $0.5 billion.
The earnings conference call will be held at dmh to discuss these results and provide additional insights into business performance.
This update provides insight into Qiagen NV's operational performance and financial health. The company, headquartered in Venlo, Limburg, specializes in Sample to Insight solutions that transform biological samples into molecular insights. With a market capitalization of $9,395.42 million and a P/E ratio of 25.16, Qiagen employs approximately 5,700 full-time staff.
Investors can look forward to upcoming earnings announcements, with the next report scheduled for May 4, 2026, where EPS is estimated at $0.5896 and revenue at $0.5 billion.